Condition
SARS-CoV-2 Infections
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 3 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06693518Phase 1CompletedPrimary
A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults
NCT05278390Not ApplicableUnknownPrimary
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic
NCT04303299Phase 3CompletedPrimary
Fight COVID-19 Trial
Showing all 3 trials